RxDoctor Payments Data

Amy Ledford, APRN

Family · Jeffersonville, INNPI 1790126696

Payments from drug & device makers

$800in general payments, 2019–2025

Across 53 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$150
  • Otsuka America Pharmaceutical, Inc.$141
  • Sunovion Pharmaceuticals Inc.$67
  • Mylan Specialty L.p.$56
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49
  • Amgen$35
  • plus $301 from 15 others

What the payments were for

  • Food & beverage$800100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$800 in reported general payments places this provider in the 60th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$120,570
Medicare patients
254
Services billed
1,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$74,900
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen544$9,859
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,852
Potassium Chloride354$8,367
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog49$8,363
MyrbetriqMirabegron26$8,332
LinzessLinaclotide13$7,001
Midodrine Hcl35$6,321
GemtesaVibegron30$5,450
Gabapentin444$4,923
Mirtazapine213$4,853
Divalproex Sodium148$4,767
Mesalamine16$4,444
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc43$4,036
EntrestoSacubitril/Valsartan17$3,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$14$9,85214 claims
AbbVieLinzess$150$7,00113 claims
NovartisEntresto$32$3,81817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,392 family providers in Indiana.

Other family in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →